The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Exploring and consolidating the CLL world
Ulrich Jäger, MD from the Medical University of Vienna, Vienna, Austria tells us about his personal highlights regarding chronic lymphocytic leukemia (CLL) from the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. He is particularly excited about new drug combinations, specifically venetoclax and obinutuzumab which have shown very positive results. However he believes that the medical community are still exploring the CLL world.
